Antiresorptive Therapy Initiating After Stereotactic Body Radiotherapy for Spinal Metastasis: Less is More?
作者信息
Liao Xiaoyao, Amar Askar, Xiao Jianru, Li Zhenxi
机构信息
Guangdong Provincial Clinical Research Center for Orthopedics, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
出版信息
Global Spine J. 2024 Apr;14(3):1089-1090. doi: 10.1177/21925682231165511. Epub 2023 Mar 22.
Abstract
摘要
相似文献
1
Antiresorptive Therapy Initiating After Stereotactic Body Radiotherapy for Spinal Metastasis: Less is More?立体定向体部放疗后启动抗骨吸收治疗用于脊柱转移瘤：少即是多？
Global Spine J. 2024 Apr;14(3):1089-1090. doi: 10.1177/21925682231165511. Epub 2023 Mar 22.
2
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.立体定向体部放疗与常规外照射放疗治疗有疼痛性脊柱转移瘤患者的效果比较：一项开放标签、多中心、随机、对照、2/3 期临床试验。
Lancet Oncol. 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. Epub 2021 Jun 11.
3
Response to Letter to the Editor Regarding "Antiresorptive Medications Prior to Stereotactic Body Radiotherapy for Spinal Metastasis are Associated With Reduced Incidence of Vertebral Body Compression Fracture".对致编辑信的回复，内容涉及“立体定向体部放疗治疗脊柱转移瘤前使用抗吸收药物与椎体压缩骨折发生率降低相关”
Global Spine J. 2024 Apr;14(3):1091-1092. doi: 10.1177/21925682231165513. Epub 2023 Mar 18.
4
A prospective multicentre feasibility study of stereotactic body radiotherapy in Japanese patients with spinal metastases.一项立体定向体部放疗治疗日本脊柱转移瘤患者的前瞻性多中心可行性研究。
Jpn J Clin Oncol. 2019 Dec 18;49(11):999-1003. doi: 10.1093/jjco/hyz130.
5
Stereotactic Body Radiotherapy for Spinal Metastases: Clinical Experience in 134 Cases From a Single Japanese Institution.立体定向体部放射治疗脊柱转移瘤：来自日本一家机构134例患者的临床经验
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806472. doi: 10.1177/1533033818806472.
6
Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design.比较传统放疗与立体定向体部放疗在脊柱转移瘤患者中的疗效：一项遵循队列多重随机对照试验设计的随机对照试验研究方案。
BMC Cancer. 2016 Nov 21;16(1):909. doi: 10.1186/s12885-016-2947-0.
7
Stereotactic Radiotherapy for Cervical Spinal Intramedullary Metastasis and Multiple Brain Metastases: A Case Report.立体定向放射治疗颈椎髓内转移瘤和多发脑转移瘤：一例报告
Cureus. 2016 Apr 27;8(4):e590. doi: 10.7759/cureus.590.
8
Role of stereotactic body radiotherapy in spinal metastasis and subsequent fracture risk: identifying and treating the at-risk patient.立体定向体部放射治疗在脊柱转移瘤及后续骨折风险中的作用：识别并治疗高危患者。
CNS Oncol. 2013 Sep;2(5):437-45. doi: 10.2217/cns.13.31.
9
Risk of radiculopathy caused by second course of spine stereotactic body radiotherapy.第二疗程脊柱立体定向体放射治疗引起的神经根病风险。
Jpn J Clin Oncol. 2022 Aug 5;52(8):911-916. doi: 10.1093/jjco/hyac070.
10
Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.立体定向体部放射治疗后椎体压缩骨折：一项大型、多机构、跨国评估。
J Neurosurg Spine. 2016 Jun;24(6):928-36. doi: 10.3171/2015.10.SPINE141261. Epub 2016 Feb 19.
本文引用的文献
1
Antiresorptive Medications Prior to Stereotactic Body Radiotherapy for Spinal Metastasis are Associated with Reduced Incidence of Vertebral Body Compression Fracture.脊柱转移瘤立体定向体部放疗前使用抗骨吸收药物与椎体压缩骨折发生率降低相关。
Global Spine J. 2024 Jul;14(6):1778-1785. doi: 10.1177/21925682231156394. Epub 2023 Feb 7.
2
Radiotherapy and Surgical Advances in the Treatment of Metastatic Spine Tumors: A Narrative Review.放疗和手术在治疗转移性脊柱肿瘤方面的进展：叙述性综述。
World Neurosurg. 2021 Jul;151:147-154. doi: 10.1016/j.wneu.2021.05.032. Epub 2021 May 21.
3
Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases.脊柱转移瘤立体定向体部放疗后的局部控制及椎体压缩骨折
J Bone Oncol. 2019 Jan 24;15:100218. doi: 10.1016/j.jbo.2019.100218. eCollection 2019 Apr.
4
Bisphosphonates in multiple myeloma: an updated network meta-analysis.双膦酸盐类药物在多发性骨髓瘤中的应用：一项更新的网状Meta分析
Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4.
5
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.地诺单抗用于接受雄激素剥夺治疗的前列腺癌男性患者。
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
Zotero 插件